Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?

Table 3 Studies for biliary tract cancer

	N	Age (yr)	No. and size of hepatic metastases	Treatment	Median OS (mo)	Mortality Rate	Survival rate %
Kurosaki et al[47], 2011	Distal bile duct (n = 7) Ampullary cancer (n = 6)	65 ± 10	Median no = 2 (1-3) Median size 3 cm (1.8-6 cm)	Adjuvant cisplatin + 5 FU or gemcitabine or S1 (n = 10)	Bile duct = 14 Ampullary = 20	-	5-yr = 44.9%
Bresadola et al[49], 2011	Gall bladder (n = 5) Papilla of Vater (n = 3) Biliary tract (n = 1)	56 (46-64)	-	-	Gall bladder = 5 (1-12) Papilla of Vater = 7 (5-71) Biliary tract = 17	3%
de Jong et al[48], 2010	Ampullary (n = 10) Duodenal (n = 5) Biliary (n = 5) Pancreas (n = 20)	63.0 ± 10.6	Median no 1(1-5) and median size 0.7 (0.2-5.9)	Neoadjuvant chemotherapy (pancreatic n = 4 ampullary n = 2 duodenal n = 1) Adjuvant chemotherapy n = 22 (55%) Gemcitabine (n = 14) 5-fluruoracil (n = 4), cyclophosphamide (n = 2) Combination irinotecan (n = 3)	Intestinal type = 23 Pancreatobiliary = 13	5%	3-yr survival Intestinal tumours = 33% Pancreatobiliary tumours = 8%
Wakai et al[45], 2008	Extrahepatic cholangiocarcinoma; adeno- carcinoma (n = 2) Gall bladder; adeno-squamous (n = 1)	63 (35-79)	-	-	Bile duct = 8 and 15 gall Bladder = 9	21%	5 yr = Extra hepatic 12% Gall bladder 9%
Gleisner et al[37], 2007	Ampullary (n = 1) Duodenal (n = 2) Distal bile duct (n = 2) Histology Adenocarcinoma	65(53–82)	Median no = 1 and median size 0.6 cm (0.3-1.2)	FOLFIRI given to duodenal cancer	9.9	9.10%	3 yr = 6.7%
Adam et al[13], 2006	Ampullary (n = 15) Pancreatic (n = 41) Gallbladder (n = 23) Biliary (n = 5)	53 (10-87)	-	-	Ampullary = 38	-	5 yr Ampullary = 46% The entire cohort = 27%
Fuji et al[46], 1999	Bile duct (n = 2) (adenocarcinoma) Ampulla of vater (n = 2) Duodenal cancer (n = 3)	58 (36-67)	Median no = 1	-	20	-	3 yr = 28%